Suppliers / Exemed Pharmaceuticals

Exemed Pharmaceuticals

India 459 employees Updated 9 July 2026

Exemed Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds 7 active US drug master files and 4 valid CEPs across a filed portfolio of 7 molecules. Its filings concentrate with CDSCO (India), ARCSA (EC) and RAMA (GE). Its GMP standing is certified by CDSCO (India), EMA and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 13 September 2024 as VAI. Customs aggregates show $10.9M of exports covering 294 molecules to 43 destinations in 2025.

7
active US DMFs
4
valid CEPs
7
registered plants 1 with an FDA FEI number
113
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 13 September 2024 VAI US FDA
  • 10 December 2013 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
vapi, India Not on file
Plot No., India Not on file
vapi 396 195 valsad, India Not on file
tal padra padra 391 440 vadodara, India Not on file
vapi 396 195valsad, India Not on file
Vadodara, India 3009219197

1 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 58 6
ARCSA (EC) 29 None
RAMA (GE) 15 None
DIGEMAPS (DO) 5 None
MINSA (CR) 3 None
UZPHARM (UZ) 3 1
EMA None 4
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.3M 17
2025 Not reported $10.9M 43
2024 Not reported $10.3M 35
2023 Not reported $9.5M 40

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Exemed Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 13 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts